Pioneering A New Era of T-Cell Immunotherapy with CERo Therapeutics’ CEO Chris Ehrlich

In this episode, Vera spoke with Chris Ehrlich, CEO at CERo Therapeutics, a company developing next-generation T cell immunotherapies, called chimeric engulfment receptor T cells (CER T).

Chris has extensive experience in biotechnology, venture capital and strategic transactions, currently serving as CEO and Chairman of the board since February 2024 and previously as CEO of PBAX.

He has held leadership roles at Locust Walk Partners and InterWest Partners, where he was involved in several notable biotech acquisitions, including the sales of Xyphos Biosciences to Astellas and Thar Pharmaceuticals to Grunenthal.

Chris also serves on multiple boards, including at Prostate Management Diagnostics, the Peter Michael Foundation and Northwestern University's Kellogg School.

Chris has a BA in Government from Dartmouth College and an MBA from the Kellogg Graduate School of Management at Northwestern University, where he is a frequent lecturer.

Tune into the episode to hear Chris discuss how the company’s approach differs from traditional CAR T-cell therapies, his path from venture capital to the C-suite and what’s next in the evolving immunotherapy landscape.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media

Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured